Radar Telegram alerts Open Radar

The Federal Antimonopoly Service has ordered the drug manufacturer Grotex (brand Solofram) to pay 2 billion rubles to the budget for the violation of competition, Kommersant writes. The department issued the order due to the launch of the generic Emporix based on empagliflozin, whose patent rights in Russia until 2030 belong to the German Boehringer Ingelheim. According to DSM Group, in January-September 2026, sales of drugs containing this substance in the public sector and at retail increased by 3.4% year-on-year, reaching 9.6 billion rubles.

תרגם לעברית

Кролик с Неглинной · · Source

🇷🇺 Russia · Map

The Federal Antimonopoly Service has ordered the drug manufacturer Grotex (brand Solofram) to pay 2 billion rubles to the budget for the violation of competition, Kommersant writes. The department issued the order due to the launch of the generic Emporix based on empagliflozin, whose patent rights in Russia until 2030 belong to the German Boehringer Ingelheim. According to DSM Group, in January-September 2026, sales of drugs containing this substance in the public sector and at retail increased by 3.4% year-on-year, reaching 9.6 billion rubles.

More on Radar

Want to see every report in real time?

Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.

Sign up free
Share on WhatsApp Get alerts on Telegram